Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2020 | 178 | 2.640 |
Why?
|
Cyclophosphamide | 14 | 2017 | 52 | 1.610 |
Why?
|
Antineoplastic Agents, Alkylating | 6 | 2017 | 19 | 1.140 |
Why?
|
Antibodies, Monoclonal | 6 | 2017 | 282 | 1.060 |
Why?
|
Mammary Neoplasms, Experimental | 4 | 2017 | 70 | 0.970 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2023 | 209 | 0.960 |
Why?
|
Cell Line, Tumor | 29 | 2023 | 2128 | 0.840 |
Why?
|
Breast Neoplasms | 11 | 2022 | 1426 | 0.830 |
Why?
|
Neoplasm Metastasis | 6 | 2013 | 211 | 0.770 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2020 | 18 | 0.770 |
Why?
|
Cell Proliferation | 11 | 2023 | 1149 | 0.750 |
Why?
|
Angiogenesis Inhibitors | 9 | 2017 | 56 | 0.740 |
Why?
|
Mice | 36 | 2023 | 5668 | 0.720 |
Why?
|
Neoplasms | 7 | 2017 | 1033 | 0.720 |
Why?
|
Neovascularization, Pathologic | 7 | 2017 | 122 | 0.610 |
Why?
|
Cytokines | 1 | 2020 | 569 | 0.590 |
Why?
|
Disease Models, Animal | 5 | 2013 | 1300 | 0.590 |
Why?
|
Indoles | 5 | 2017 | 154 | 0.510 |
Why?
|
Animals | 40 | 2023 | 14307 | 0.510 |
Why?
|
Xenograft Model Antitumor Assays | 14 | 2013 | 242 | 0.490 |
Why?
|
Deoxycytidine | 2 | 2011 | 21 | 0.490 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2009 | 157 | 0.470 |
Why?
|
DNA Repair | 2 | 2005 | 181 | 0.470 |
Why?
|
Mice, SCID | 12 | 2018 | 143 | 0.470 |
Why?
|
Melanoma | 3 | 2023 | 91 | 0.450 |
Why?
|
Lung Neoplasms | 3 | 2018 | 336 | 0.440 |
Why?
|
Antineoplastic Agents | 5 | 2016 | 756 | 0.420 |
Why?
|
Prodrugs | 1 | 2011 | 22 | 0.420 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2013 | 12 | 0.410 |
Why?
|
Humans | 49 | 2023 | 34853 | 0.410 |
Why?
|
Antibodies | 3 | 2009 | 135 | 0.400 |
Why?
|
Pyrroles | 4 | 2017 | 54 | 0.400 |
Why?
|
Neoplasm Transplantation | 7 | 2018 | 114 | 0.390 |
Why?
|
Mice, Inbred BALB C | 8 | 2017 | 649 | 0.360 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 233 | 0.350 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 4 | 0.340 |
Why?
|
Viscera | 1 | 2008 | 4 | 0.340 |
Why?
|
Spheroids, Cellular | 3 | 2005 | 28 | 0.340 |
Why?
|
Female | 28 | 2022 | 19873 | 0.330 |
Why?
|
Base Pair Mismatch | 2 | 2005 | 13 | 0.320 |
Why?
|
Camptothecin | 2 | 2017 | 20 | 0.320 |
Why?
|
Dose-Response Relationship, Drug | 11 | 2020 | 984 | 0.320 |
Why?
|
Endothelial Cells | 7 | 2017 | 296 | 0.310 |
Why?
|
Melanoma, Experimental | 3 | 2008 | 9 | 0.300 |
Why?
|
Fibroblasts | 1 | 2009 | 252 | 0.300 |
Why?
|
Thyroid Neoplasms | 2 | 2020 | 35 | 0.300 |
Why?
|
Receptor, erbB-2 | 4 | 2022 | 122 | 0.290 |
Why?
|
Carcinoid Tumor | 1 | 2006 | 3 | 0.290 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2006 | 2 | 0.290 |
Why?
|
ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.290 |
Why?
|
Bromocriptine | 1 | 2006 | 7 | 0.290 |
Why?
|
Cushing Syndrome | 1 | 2006 | 5 | 0.290 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2013 | 298 | 0.280 |
Why?
|
Prostatic Neoplasms | 8 | 2013 | 794 | 0.280 |
Why?
|
Tumor Cells, Cultured | 9 | 2011 | 480 | 0.280 |
Why?
|
DNA Repair Enzymes | 1 | 2005 | 20 | 0.270 |
Why?
|
Cyclin D1 | 3 | 2018 | 42 | 0.270 |
Why?
|
Adenosine Triphosphatases | 1 | 2005 | 78 | 0.260 |
Why?
|
Tumor Burden | 5 | 2012 | 79 | 0.260 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2022 | 180 | 0.260 |
Why?
|
Cell Movement | 3 | 2018 | 545 | 0.260 |
Why?
|
Alkylating Agents | 1 | 2004 | 13 | 0.260 |
Why?
|
Administration, Oral | 7 | 2016 | 212 | 0.250 |
Why?
|
Colonic Neoplasms | 3 | 2017 | 181 | 0.240 |
Why?
|
Mice, Nude | 10 | 2020 | 323 | 0.240 |
Why?
|
Survival Rate | 3 | 2020 | 310 | 0.240 |
Why?
|
Carrier Proteins | 1 | 2005 | 287 | 0.230 |
Why?
|
Nuclear Proteins | 1 | 2005 | 287 | 0.230 |
Why?
|
Liver Neoplasms | 2 | 2018 | 195 | 0.220 |
Why?
|
Apoptosis | 5 | 2017 | 1317 | 0.220 |
Why?
|
Phenylurea Compounds | 2 | 2020 | 18 | 0.210 |
Why?
|
Prognosis | 3 | 2020 | 707 | 0.210 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 522 | 0.210 |
Why?
|
Time Factors | 6 | 2017 | 1681 | 0.190 |
Why?
|
Follow-Up Studies | 2 | 2020 | 964 | 0.190 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2018 | 107 | 0.190 |
Why?
|
Quinolines | 1 | 2020 | 60 | 0.180 |
Why?
|
Blotting, Western | 4 | 2005 | 834 | 0.180 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1999 | 42 | 0.180 |
Why?
|
Transplantation, Heterologous | 4 | 2018 | 87 | 0.170 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 31 | 0.170 |
Why?
|
Thrombospondin 1 | 2 | 2012 | 22 | 0.170 |
Why?
|
Molecular Probe Techniques | 1 | 2018 | 7 | 0.170 |
Why?
|
Axilla | 1 | 2018 | 8 | 0.170 |
Why?
|
Flavones | 1 | 2018 | 8 | 0.170 |
Why?
|
Neoplasms, Experimental | 1 | 2018 | 36 | 0.170 |
Why?
|
Molecular Probes | 1 | 2018 | 23 | 0.170 |
Why?
|
Taxoids | 2 | 2014 | 36 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 82 | 0.150 |
Why?
|
Male | 20 | 2023 | 18870 | 0.150 |
Why?
|
Cell Death | 1 | 2017 | 260 | 0.150 |
Why?
|
Annexin A6 | 1 | 1996 | 14 | 0.140 |
Why?
|
Base Sequence | 5 | 2004 | 932 | 0.140 |
Why?
|
Blotting, Northern | 3 | 2004 | 139 | 0.140 |
Why?
|
Cisplatin | 3 | 2005 | 70 | 0.140 |
Why?
|
Bone Neoplasms | 1 | 2016 | 42 | 0.140 |
Why?
|
Gene Expression Profiling | 4 | 2015 | 600 | 0.140 |
Why?
|
Staining and Labeling | 1 | 2016 | 100 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 117 | 0.140 |
Why?
|
Signal Transduction | 4 | 2017 | 1802 | 0.140 |
Why?
|
Microscopy, Confocal | 1 | 2016 | 210 | 0.140 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 325 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2018 | 781 | 0.140 |
Why?
|
Up-Regulation | 5 | 2015 | 490 | 0.140 |
Why?
|
Spectrum Analysis, Raman | 1 | 2016 | 84 | 0.140 |
Why?
|
Curcumin | 1 | 2016 | 66 | 0.130 |
Why?
|
Molecular Sequence Data | 5 | 2004 | 1490 | 0.130 |
Why?
|
NF-kappa B | 1 | 2017 | 306 | 0.130 |
Why?
|
Cell Adhesion | 1 | 2015 | 209 | 0.130 |
Why?
|
Disease Progression | 3 | 2014 | 580 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2013 | 245 | 0.130 |
Why?
|
Drug Administration Schedule | 6 | 2018 | 145 | 0.120 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 145 | 0.120 |
Why?
|
Ultrasonic Therapy | 1 | 2013 | 5 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2011 | 109 | 0.110 |
Why?
|
Receptor, Endothelin B | 1 | 2012 | 3 | 0.110 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 9 | 0.110 |
Why?
|
Caveolin 1 | 1 | 2012 | 27 | 0.110 |
Why?
|
Ceramides | 1 | 2012 | 41 | 0.110 |
Why?
|
Adenocarcinoma | 3 | 2014 | 239 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 18 | 0.110 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 162 | 0.110 |
Why?
|
Blood Vessels | 1 | 2011 | 32 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 139 | 0.100 |
Why?
|
Brain Neoplasms | 1 | 2013 | 105 | 0.100 |
Why?
|
Benzenesulfonates | 1 | 2010 | 8 | 0.100 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 106 | 0.100 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2010 | 21 | 0.100 |
Why?
|
Genetic Engineering | 1 | 2010 | 31 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 605 | 0.090 |
Why?
|
Drug Synergism | 3 | 2017 | 171 | 0.090 |
Why?
|
Pyridines | 1 | 2010 | 113 | 0.090 |
Why?
|
Transfection | 2 | 2015 | 496 | 0.090 |
Why?
|
RNA, Messenger | 4 | 2022 | 1152 | 0.090 |
Why?
|
Transforming Growth Factor alpha | 1 | 2009 | 16 | 0.090 |
Why?
|
Polymerase Chain Reaction | 2 | 2015 | 430 | 0.090 |
Why?
|
Lymphokines | 1 | 2009 | 11 | 0.090 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2009 | 31 | 0.090 |
Why?
|
Mice, Transgenic | 3 | 2020 | 608 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2010 | 147 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 182 | 0.080 |
Why?
|
Immunotherapy | 1 | 2009 | 91 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2020 | 107 | 0.080 |
Why?
|
Cell Cycle | 3 | 2017 | 309 | 0.080 |
Why?
|
Down-Regulation | 2 | 2022 | 420 | 0.070 |
Why?
|
Mutation | 2 | 2023 | 1023 | 0.070 |
Why?
|
Azacitidine | 1 | 2005 | 21 | 0.070 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2005 | 8 | 0.070 |
Why?
|
Hydroxamic Acids | 1 | 2005 | 30 | 0.070 |
Why?
|
Blood Coagulation | 1 | 2005 | 22 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2014 | 1349 | 0.060 |
Why?
|
CHO Cells | 1 | 2004 | 107 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2016 | 269 | 0.060 |
Why?
|
Gene Expression | 2 | 2018 | 639 | 0.060 |
Why?
|
Cricetinae | 1 | 2004 | 217 | 0.060 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2023 | 6 | 0.060 |
Why?
|
Models, Genetic | 1 | 2004 | 149 | 0.060 |
Why?
|
HT29 Cells | 3 | 2012 | 40 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 23 | 0.060 |
Why?
|
In Situ Hybridization | 2 | 2003 | 125 | 0.060 |
Why?
|
Cadherins | 1 | 2004 | 82 | 0.060 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2003 | 32 | 0.060 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 383 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2005 | 484 | 0.060 |
Why?
|
Topotecan | 2 | 2013 | 4 | 0.060 |
Why?
|
Interferon Regulatory Factors | 1 | 2022 | 15 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2004 | 455 | 0.050 |
Why?
|
Anoikis | 1 | 2022 | 21 | 0.050 |
Why?
|
DNA Methylation | 1 | 2005 | 301 | 0.050 |
Why?
|
RNA | 1 | 2004 | 234 | 0.050 |
Why?
|
Immunohistochemistry | 2 | 2012 | 859 | 0.050 |
Why?
|
Survival Analysis | 2 | 2013 | 322 | 0.050 |
Why?
|
Vinblastine | 2 | 2016 | 9 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 229 | 0.050 |
Why?
|
Middle Aged | 3 | 2016 | 9642 | 0.050 |
Why?
|
Cloning, Molecular | 2 | 1999 | 310 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 203 | 0.050 |
Why?
|
Aged | 3 | 2017 | 6448 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2016 | 392 | 0.050 |
Why?
|
Protein Phosphatase 2 | 1 | 1999 | 22 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2004 | 413 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 1999 | 13 | 0.040 |
Why?
|
Tegafur | 2 | 2010 | 2 | 0.040 |
Why?
|
Uracil | 2 | 2010 | 8 | 0.040 |
Why?
|
Rabbits | 2 | 1996 | 278 | 0.040 |
Why?
|
Fluorouracil | 2 | 2012 | 32 | 0.040 |
Why?
|
Luminescent Measurements | 1 | 2018 | 26 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2011 | 9 | 0.040 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2017 | 3 | 0.040 |
Why?
|
bcl-X Protein | 1 | 2017 | 23 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 79 | 0.040 |
Why?
|
Contrast Media | 1 | 2018 | 95 | 0.040 |
Why?
|
Caspases | 1 | 2017 | 132 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2018 | 197 | 0.040 |
Why?
|
Nevus | 1 | 1996 | 5 | 0.040 |
Why?
|
Stem Cells | 2 | 2010 | 132 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 63 | 0.040 |
Why?
|
Dexamethasone | 1 | 2016 | 43 | 0.040 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 74 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2016 | 197 | 0.040 |
Why?
|
Connective Tissue Growth Factor | 1 | 2015 | 18 | 0.030 |
Why?
|
RNA Stability | 1 | 2015 | 24 | 0.030 |
Why?
|
Cell Line | 1 | 1999 | 1289 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2015 | 52 | 0.030 |
Why?
|
Autoantibodies | 1 | 2015 | 103 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-2B | 1 | 1994 | 1 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-2 | 1 | 1994 | 18 | 0.030 |
Why?
|
Fecal Impaction | 1 | 2013 | 1 | 0.030 |
Why?
|
Rats, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 1994 | 112 | 0.030 |
Why?
|
Genes, erbB-2 | 1 | 2013 | 6 | 0.030 |
Why?
|
Species Specificity | 1 | 2013 | 233 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2012 | 8 | 0.030 |
Why?
|
Protein Binding | 1 | 2015 | 913 | 0.030 |
Why?
|
Leucovorin | 1 | 2012 | 4 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2012 | 15 | 0.030 |
Why?
|
Cell Division | 2 | 2004 | 296 | 0.030 |
Why?
|
Injections | 1 | 2012 | 35 | 0.030 |
Why?
|
Pyrrolidines | 1 | 2012 | 26 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 247 | 0.030 |
Why?
|
Prospective Studies | 1 | 2016 | 1353 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 36 | 0.030 |
Why?
|
Skin | 1 | 2013 | 173 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 97 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 94 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2008 | 1530 | 0.020 |
Why?
|
Proteins | 1 | 1994 | 352 | 0.020 |
Why?
|
Niacinamide | 1 | 2010 | 10 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2005 | 1442 | 0.020 |
Why?
|
Phosphorylation | 1 | 2013 | 878 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2016 | 2333 | 0.020 |
Why?
|
Liver | 2 | 2007 | 447 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 195 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2008 | 19 | 0.020 |
Why?
|
Adenoviridae | 1 | 2008 | 59 | 0.020 |
Why?
|
Ligands | 1 | 2009 | 317 | 0.020 |
Why?
|
Solubility | 1 | 2008 | 115 | 0.020 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2007 | 14 | 0.020 |
Why?
|
Biotransformation | 1 | 2007 | 65 | 0.020 |
Why?
|
Drug Combinations | 1 | 2007 | 89 | 0.020 |
Why?
|
Laminin | 1 | 2007 | 59 | 0.020 |
Why?
|
Proteoglycans | 1 | 2007 | 46 | 0.020 |
Why?
|
Microsomes, Liver | 1 | 2007 | 69 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2007 | 82 | 0.020 |
Why?
|
Collagen | 1 | 2007 | 162 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2006 | 41 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2009 | 550 | 0.020 |
Why?
|
Triazines | 1 | 2006 | 19 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2006 | 55 | 0.020 |
Why?
|
Thromboplastin | 1 | 2005 | 5 | 0.020 |
Why?
|
Propionates | 1 | 2005 | 25 | 0.020 |
Why?
|
Rats | 1 | 2013 | 3261 | 0.020 |
Why?
|
Quinazolines | 1 | 2005 | 31 | 0.020 |
Why?
|
Piperidines | 1 | 2005 | 76 | 0.020 |
Why?
|
Oxygen | 1 | 2006 | 193 | 0.020 |
Why?
|
Blood Cell Count | 1 | 2004 | 13 | 0.020 |
Why?
|
Bone Marrow | 1 | 2004 | 34 | 0.020 |
Why?
|
Lymphopenia | 1 | 2004 | 15 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2004 | 142 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 555 | 0.020 |
Why?
|
Etoposide | 1 | 2004 | 21 | 0.020 |
Why?
|
HSC70 Heat-Shock Proteins | 1 | 2003 | 3 | 0.020 |
Why?
|
Umbilical Veins | 1 | 2003 | 16 | 0.020 |
Why?
|
Blood Platelets | 1 | 2004 | 74 | 0.020 |
Why?
|
Microdissection | 1 | 2003 | 11 | 0.020 |
Why?
|
Microcirculation | 1 | 2003 | 39 | 0.010 |
Why?
|
Paclitaxel | 1 | 2004 | 48 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2004 | 70 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2003 | 25 | 0.010 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2003 | 45 | 0.010 |
Why?
|
Wound Healing | 1 | 2004 | 69 | 0.010 |
Why?
|
Drug Resistance | 1 | 2004 | 93 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 2004 | 115 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2004 | 110 | 0.010 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 8 | 0.010 |
Why?
|
Receptors, Growth Factor | 1 | 2002 | 13 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2002 | 26 | 0.010 |
Why?
|
Body Weight | 1 | 2004 | 404 | 0.010 |
Why?
|
Drinking | 1 | 2002 | 37 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 968 | 0.010 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 1994 | 28 | 0.010 |
Why?
|
Oligonucleotides | 1 | 1994 | 48 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1994 | 175 | 0.010 |
Why?
|
Fungal Proteins | 1 | 1994 | 130 | 0.010 |
Why?
|
Repressor Proteins | 1 | 1994 | 226 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1994 | 1124 | 0.010 |
Why?
|